436P - Population-based incidence and outcome of primary central nervous system lymphoma - A study by the Austrian brain tumor registry, 2005-2010

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Aetiology, Epidemiology, Screening and Prevention
Central Nervous System Malignancies
Basic Scientific Principles
Presenter Adelheid Woehrer
Citation Annals of Oncology (2014) 25 (suppl_4): iv137-iv145. 10.1093/annonc/mdu330
Authors A. Woehrer1, M. Hackl2, T. Waldhör3, J. Hainfellner1, A.S. Berghoff4, M. Preusser4
  • 1Institute Of Neurology, Medical University of Vienna, 1090 - Vienna/AT
  • 2Austrian National Cancer Registry, Statistics Austria, Vienna/AT
  • 3Department Of Epidemiology, Medical University of Vienna, Vienna/AT
  • 4Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT



The incidence of primary central nervous system lymphoma (PCNSL) has been reported to increase in some countries while rates remained stable in others. Likewise, treatment of PCNSL patients has improved over the years with reported median overall survival (OS) rates of 30–60 months in clinical trials. The objective of this study was to analyze the contemporary incidence and survival of PCNSL patients at the population-level.


Patients were identified by chart review of all cases with a recorded diagnosis of lymphoma within the central nervous system from 2005-2010 by the Austrian Brain Tumor Registry. By data linkage with the National Cancer Registry, all cases with evidence of a prior systemic lymphoma were excluded. Population data and last follow up (12/31/2012) were provided by Statistics Austria. Survival was analyzed using the Kaplan-Meier method.


From 2005–2010, there were 201 cases with a newly diagnosed, histologically confirmed PCNSL in Austria. The age-standardized incidence rate referred to 0.3 per 1,000,000 person-years (95% CI 0.2-0.4). Median age at diagnosis was 67ys (range 14-84ys) The median OS of all patients was 11.0 months. OS was 33.3% at 3 years and 21.1% at 5 years, respectively. While there were no significant differences in survival with regard to gender (p = 0.62; log-rank test) or tertiary care centers (p = 0.28; log-rank test), age was a major prognostic factor (median OS 44.0 months in patients aged <65 years versus 5.0 months in patients >65 years of age).


The incidence of PCNSL is low and patient median survival times at the population-level are considerably lower than those reported in clinical trials. Outcome is particularly poor in elderly patients. However, long-term survival beyond 5 years is achieved in approximately one fifth of patients. More research, including prospective and multicentric clinical trials, may help to optimize patient outcome in PCNSL.


All authors have declared no conflicts of interest.